- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Prescient signs cell manufacturing deal ahead of OmniCAR trials
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell...
Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce...
Prescient secures OmniCAR cell lines for upcoming clinical trials
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...
Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed...
Prescient Therapeutics enters into OmniCAR cell production agreement with Q-Gen Cell
Prescient Therapeutics Ltd (ASX:PTX) has entered into a five-year manufacturing services agreement with specialist cell therapy...
Prescient Therapeutics signs deal with Q-Gen to enable OmniCAR clinical trials
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer...
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion...
Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be...